Novartis licenses out early antiviral work to Gilead by Ben Adams Friday, July 19, 2019 Days after announcing its R&D chief was stepping down, Gilead announced it will be buying a few of Novartis’ unwanted early-stage infection assets.
New discoveries in asthma and antivirals—News of note by Arlene Weintraub Monday, June 17, 2019 The week’s biotech news included a map of the human lung that could aid asthma drug development and a compound that thwarts rhinoviruses like colds.
Viracta's combo garners high response in EBV-linked lymphoma by Arlene Weintraub Monday, June 3, 2019 A combination of Viracta Therapeutics' nanatinostat and an antiviral drug produced a 58% response rate in an early trial.
BiomX nets $32M to build bacteria-killing viruses for IBD, acne by Conor Hale Wednesday, February 20, 2019 BiomX raised $32 million for preclinical development of its customized phage cocktail therapies aimed at eradicating the bacteria behind IBD and acne.
Chimerix’s CEO departs and is replaced by a trio of officers by Conor Hale Wednesday, February 6, 2019 Chimerix announced its president and CEO, M. Michelle Berrey, has resigned and is being replaced by a triumvirate of senior company officers.
Gilead, Aelix ally to trial HIV-suppressing combination by Nick Paul Taylor Thursday, October 18, 2018 The planned clinical trial will test Gilead’s TLR7 agonist in combination with Aelix’s T-cell vaccine.
New insights into antiviral gene could help combat Zika by Arlene Weintraub Monday, June 25, 2018 New insights into the antiviral gene RSAD2 could be used to create new therapies to treat Zika, dengue and other flaviviruses.
Enyo raises $47M to bring hep B, NASH drug to phase 2 by Conor Hale Monday, June 4, 2018 Enyo Pharma raised nearly $47 million to launch the first two phase 2 clinical trials of EYP001, its lead candidate in hep B and NASH, before 2019.
Ansun gathers $85M to fund phase 3 antiviral study by Conor Hale Monday, May 14, 2018 Ansun BioPharma raised $85 million in series A financing and plans to use the funds for an upcoming phase 3 trial of its DAS181 antiviral medication.
Attacking the common cold by unshielding its genome by Arlene Weintraub Monday, May 14, 2018 Researchers at Imperial College London believe they’ve found a way to block multiple strains of the flu by targeting a protein it needs to survive.